Did AbbVie and Zoetis Add Value for Abbott Labs and Pfizer Shareholders?

One looks like a winner, but the jury is still out for another

Brenton Flynn
Brenton Flynn
Feb 12, 2013 at 5:00PM
Health Care

It's the year of the spinoff in health care, with a variety of new businesses making their market debuts so far in 2013, and at least one more is planned for later in the year.

In the following video, health care bureau chief Brenton Flynn outlines the separation of AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) from Abbott Labs (NYSE:ABT) and Pfizer (NYSE:PFE), respectively, and explains to investors both the rationale for the moves and whether they've added value so far for shareholders.